1Y Close · As of Aug 26, 2026
L&C BIO operates in the Pharmaceuticals sector.
Legal name: L&C BIO Co., Ltd
In fiscal year 2025, L&C BIO (290650) reported revenue of 85.5 billion KRW, up 18.6% from 72.1 billion KRW a year earlier.
Operating profit was 4.4 billion KRW and net income was -138.2 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 1.37 trillion KRW, with a P/B of 6.56.
These figures can be verified in the DART filing (receipt no. 20260324000006).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 85.5B | 4.4B | -138.2B |
| 2024 | 72.1B | 2.5B | 141.0B |
| 2023 | 68.9B | 7.7B | 48.5B |
| 2022 | 52.6B | 9.5B | 5.7B |
| 2021 | 45.7B | 13.2B | 15.6B |
Recent Filings
Semi-Annual Report (2026.06)
Officer/Major Shareholder Ownership Report
Derivative Trading Loss
Checks
2 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-12 | Officer/Major Shareholder Ownership Report |
| 2026-08-11 | Derivative Trading Loss |
| 2026-08-11 | Consolidated Operating (Preliminary) Earnings (Fair Disclosure) |
| 2026-08-11 | Operating (Preliminary) Earnings (Fair Disclosure) |